You are here

Allergan

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

Endpoints

Lysosomal Therapeutics

Flag link:

Vesper Healthcare Acquisition, a SPAC led by the former CEO of Allergan, files for a $400 million IPO

Vesper Healthcare Acquisition, a SPAC led by the former CEO of Allergan, files for a $400 million IPO

NASDAQ

Vesper Healthcare Acquisition

Flag link:

AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

Xconomy

overactive bladder

Flag link:

AbbVie cuts Editas CRISPR pact it inherited from Allergan

AbbVie cuts Editas CRISPR pact it inherited from Allergan

Fierce Biotech

Editas Medicine

Flag link:

AbbVie draws first blood in trade secrets war between Allergan's Botox and Evolus

AbbVie draws first blood in trade secrets war between Allergan's Botox and Evolus

Fierce Pharma

Daewoong Pharmaceuticals

Flag link:

FDA rejects AbbVie's eye drug, citing safety concerns

FDA rejects AbbVie's eye drug, citing safety concerns

BioPharma Dive

Molecular Partners

wet age-related macular degeneration

Flag link:

Allergan ex-CEO Saunders takes board seat at BridgeBio

Allergan ex-CEO Saunders takes board seat at BridgeBio

Fierce Biotech

Flag link:

Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact

Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact

Fierce Biotech

Assembly Biosciences

Flag link:

Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns

Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns

Endpoints

Flag link:

Breast Implant Makers Land in Hot Water with FDA

Breast Implant Makers Land in Hot Water with FDA

Medical Devices and Diagnostics Industry

breast implants

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go

AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go

Fierce Pharma

Flag link:

AbbVie CEO: Don't worry, Allergan's aesthetics clients still have money—and 'strong desire' for treatment

AbbVie CEO: Don't worry, Allergan's aesthetics clients still have money—and 'strong desire' for treatment

Fierce Pharma

Flag link:

A Covid-19 threat to business acquisitions

A Covid-19 threat to business acquisitions

EP Vantage

Gilead Sciences

Flag link:

AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger

AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger

BioSpace

Flag link:

AbbVie, Allergan merger may face regulatory delay due to COVID-19: report

AbbVie, Allergan merger may face regulatory delay due to COVID-19: report

Fierce Pharma

Flag link:

Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster

Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster

Pharmaforum

Flag link:

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

BioSpace

Bristol-Myers Squibb

Flag link:

FDA approves Allergan’s biodegradable glaucoma implant drug

FDA approves Allergan’s biodegradable glaucoma implant drug

PM Live

Flag link:

AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match

AbbVie and Allergan finally set (rough) date for wedding as one parent agrees to the match

Endpoints

Flag link:

Pages